Amrani Y., Syed F., Huang C., Li K., Liu V., Jain D., Keslacy S., Sims M.W., Baidouri H., Cooper P.R., Zhao H., Siddiqui S., Brightling C.E., Griswold D., Li L., Panettieri R.A. Expression and activation of the oxytocin receptor in airway smooth muscle cells: regulation by TNFalpha and IL-13. Respiratory Research 2010, 11:104.
Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics (Oxford, England) 2005, 21:263-265.
Belmaker R.H., Agam G. Major depressive disorder. The New England Journal of Medicine 2008, 358:55-68.
Brunello N., Alboni S., Capone G., Benatti C., Blom J.M., Tascedda F., Kriwin P., Mendlewicz J. Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depression. International Clinical Psychopharmacology 2006, 21:219-225.
CHMP, Note for guidance on clinical investigation of medicinal products in the treatment of depression, 2002. http://www.emea.europa.eu/pdfs/human/ewp/051897en.pdf.
Costa B., Pini S., Gabelloni P., Abelli M., Lari L., Cardini A., Muti M., Gesi C., Landi S., Galderisi S., Mucci A., Lucacchini A., Cassano G.B., Martini C. Oxytocin receptor polymorphisms and adult attachment style in patients with depression. Psychoneuroendocrinology 2009, 34:1506-1514.
Dean B. Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studies. The International Journal of Neuropsychopharmacology/Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 2011, 14:997-1012.
Frasch A., Zetzsche T., Steiger A., Jirikowski G.F. Reduction of plasma oxytocin levels in patients suffering from major depression. Advances in Experimental Medicine and Biology 1995, 395:257-258.
Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry 1960, 23:56-62.
Heinrichs M., Baumgartner T., Kirschbaum C., Ehlert U. Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. Biological Psychiatry 2003, 54:1389-1398.
Kessler R.C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K.R., Rush A.J., Walters E.E., Wang P.S. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). The Journal of the American Medical Association 2003, 289:3095-3105.
Kimura T., Tanizawa O., Mori K., Brownstein M.J., Okayama H. Structure and expression of a human oxytocin receptor. Nature 1992, 356:526-529.
Kirsch P., Esslinger C., Chen Q., Mier D., Lis S., Siddhanti S., Gruppe H., Mattay V.S., Gallhofer B., Meyer-Lindenberg A. Oxytocin modulates neural circuitry for social cognition and fear in humans. The Journal of Neuroscience 2005, 25:11489-11493.
Kocabas N.A., Faghel C., Barreto M., Kasper S., Linotte S., Mendlewicz J., Noro M., Oswald P., Souery D., Zohar J., Massat I. The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study. International Clinical Psychopharmacology 2010, 25:218-227.
Lee H.J., Macbeth A.H., Pagani J.H., Young W.S. Oxytocin: the great facilitator of life. Progress in Neurobiology 2009, 88:127-151.
Ma S.L., Tang N.L., Zhang Y.P., Ji L.D., Tam C.W., Lui V.W., Chiu H.F., Lam L.C. Association of prostaglandin-endoperoxide synthase 2 (PTGS2) polymorphisms and Alzheimer's disease in Chinese. Neurobiology of Aging 2008, 29:856-860.
Mendlewicz J., Kriwin P., Oswald P., Souery D., Alboni S., Brunello N. Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. International Clinical Psychopharmacology 2006, 21:227-231.
Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biological Psychiatry 2009, 65:732-741.
Muller N., Myint A.M., Schwarz M.J. Inflammatory biomarkers and depression. Neurotoxicity Research 2011, 19:308-318.
Muller N., Schwarz M.J., Dehning S., Douhe A., Cerovecki A., Goldstein-Muller B., Spellmann I., Hetzel G., Maino K., Kleindienst N., Moller H.J., Arolt V., Riedel M. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Molecular Psychiatry 2006, 11:680-684.
Neumann I.D. Involvement of the brain oxytocin system in stress coping: interactions with the hypothalamo-pituitary-adrenal axis. Progress in Brain Research 2002, 139:147-162.
Parker K.J., Kenna H.A., Zeitzer J.M., Keller J., Blasey C.M., Amico J.A., Schatzberg A.F. Preliminary evidence that plasma oxytocin levels are elevated in major depression. Psychiatry Research 2010, 178:359-362.
Rush A.J. STAR*D: what have we learned?. The American Journal of Psychiatry 2007, 164:201-204.
Scantamburlo G., Hansenne M., Fuchs S., Pitchot W., Marechal P., Pequeux C., Ansseau M., Legros J.J. Plasma oxytocin levels and anxiety in patients with major depression. Psychoneuroendocrinology 2007, 32:407-410.
Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. The Journal of Clinical Psychiatry 1998, 59(Suppl. 20):22-33. quiz 34-57.
Souery D., Oswald P., Massat I., Bailer U., Bollen J., Demyttenaere K., Kasper S., Lecrubier Y., Montgomery S., Serretti A., Zohar J., Mendlewicz J. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. The Journal of Clinical Psychiatry 2007, 68:1062-1070.
StatSoft I. STATISTICA per Windows 1995, StatSoft Italia srl.
Thompson R.J., Parker K.J., Hallmayer J.F., Waugh C.E., Gotlib I.H. Oxytocin receptor gene polymorphism (rs2254298) interacts with familial risk for psychopathology to predict symptoms of depression and anxiety in adolescent girls. Psychoneuroendocrinology 2010, 36:144-147.
van Londen L., Goekoop J.G., van Kempen G.M., Frankhuijzen-Sierevogel A.C., Wiegant V.M., van der Velde E.A., De Wied D. Plasma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacology 1997, 17:284-292.
